We are investigating the fairness of the proposed sale of AtaiBeckley, Inc. (Nasdaq: ATAI) (“AtaiBeckley”) to Eli Lilly and Company (“Lilly”), pursuant to which AtaiBeckley shareholders will receive $6.75 per share in cash, plus a contingent value right (“CVR”) worth up to an additional $2.50 per share.
Notably, the sale price with the CVR is well below the price targets of multiple Wall Street analysts covering AtaiBeckley before the sale was announced, including:
- Patrick Trucchio of H.C. Wainwright ($25.00 price target)
- Sumant Kulkarni of Canaccord Genuity ($17.00 price target)
- Jay Olson of Oppenheimer ($16.00 price target)
- Eddie Hickman of Guggenheim ($16.00 price target)
- Harry Gillis of Berenberg Bank ($14.00 price target)
(Source: TipRanks)
Moreover, shareholders have expressed disappointment in the sale price on the Seeking Alpha investment website. One shareholder complained, “Man, did they sell out cheap.” A second asserted that “even at $50.00 per share, it would be a steal for Eli Lilly.”
If you remain an AtaiBeckley shareholder and have concerns about the fairness of the proposed acquisition, you may contact our firm by completing and submitting the form below.
“We are investigating whether the AtaiBeckley Board of Directors acted in the best interests of AtaiBeckley shareholders in approving the sale,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter. “This includes whether the cash consideration and CVR agreed upon are fair to AtaiBeckley shareholders, and whether all material information regarding the transaction has been fully disclosed. We encourage AtaiBeckley stockholders to contact us if they have any concerns.”